Importantly, it is clinically feasible to assess these markers at diagnosis to tailor therapy since diagnostic assays for MLH1 and PMS2 loss are routinely implemented in clinic for colorectal and endometrial cancer patients29,30. Here, MLH1 is linked to endometrial cancer.